A Phase 1/2 interventional study of vepdegestrant and PF-07220060 in Breast Cancer, sponsored by Pfizer. Active, not recruiting at 58 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Pfizer · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing vepdegestrant in Breast Neoplasms — 1 open to participants now, 6 under way, 2 of them phase 3. vepdegestrant · Breast Neoplasms.
Among the 12 studies testing vepdegestrant in Breast Neoplasms, this one is the 5th largest by enrollment, is one of 2 that started in 2024, is one of 5 in phase 1/2, and was the 12th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →1 of the 12 studies testing vepdegestrant in Breast Neoplasms is open now, in 1 country. Recruiting first, the newest first:
QuantumLeap Healthcare Collaborative · Sites in United States
Ages 18+
By country, each count listing its studies:
vepdegestrant: first FDA approval 2026 (VEPPANU). What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, vepdegestrant is the treatment under test here. Read study by study →
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 7 · Phase 3 2
First in 2010; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 71 is close to the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 48 across the 12 interventional studies. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 12 have an industry lead sponsor. The 4 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
182 studies in Breast Neoplasms by Pfizer: 6 open now, 26 under way, 7 of them phase 3. Of 145 finished, 94 (65%) have results posted.
Among the 182 studies in Breast Neoplasms by Pfizer, this one is the 64th largest by enrollment of the 121 interventional ones that give a count, is one of 11 that started in 2024, is one of 13 in phase 1/2, reaches primary completion later than 5 of the 25 other live ones, and was the 166th registered.
Pfizer’s Breast Neoplasms studies by the year they started, since 1998.
2 of the studies testing vepdegestrant in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05909397Phase 3PfizerVepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer | 2026-12-30 |
| NCT05548127PfizerTACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A) | 2027-03-24 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies testing vepdegestrant in Breast Neoplasms, from their registry updates:
Among Pfizer’s 182 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn about the safety and effects of giving vepdegestrant along with PF-07220060. Vepdegestrant is studied to see if it can be a possible treatment for advanced metastatic breast cancer. This type of cancer would have spread from where it started (breast) to other parts of the body and would be tough to treat. The study is seeking for participants who have breast cancer that:
All the participants will receive vepdegestrant and PF-07220060. Both medicines will be taken by mouth. The medicines will be taken at home. The experience of people receiving the study medicines will be studied. This will help see if the study medicines are safe and effective. Participants will continue to take vepdegestrant and PF-07220060 until:
C4891026 is a prospective, open-label, multicenter, Phase 1b/2 study to evaluate the safety, antitumor activity, and pharmacokinetic (PK) of vepdegestrant in combination with PF-07220060 in the treatment of participants with Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Advanced or Metastatic Breast Cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
prior anticancer therapies: Phase 1b: at least 1 line of SOC for A/MBC; Prior fulvestrant allowed; ≤1 prior chemotherapy line (no antibody-drug conjugates permitted) for A/MBC setting allowed. Phase 2: At least one and maximum 2 lines of ET in A/MBC setting and most recent ET-based regimen for >6 months.
1, and only 1, prior CDK4/6 inhibitor-based regimen required. Up to 1 prior regimen of cytotoxic chemotherapy (no antibody-drug conjugates permitted) in the A/MBC setting; Prior fulvestrant allowed.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
vepdegestrant administered orally once daily (QD) continuously and PF-07220060 administered orally twice daily (BID) continuously on 28-day cycles
Drug: vepdegestrant · Drug: PF-07220060
Daily oral dosages of vepdegestrant continuously, dose escalation/de-escalation in Phase 1b until recommended phase 2 dose (RP2D) determined, cycles lasting 28 days
Also known as: ARV-471 / PF07850327
Daily oral dosages of PF-07220060 continuously, dose escalation/de-escalation in Phase 1b until recommended phase 2 dose (RP2D) determined, cycles lasting 28 days
Number of Participants With Dose-Limiting Toxicities (DLTs): Phase 1b
Hematological DLT: neutropenic fever; Grade\>=3 thrombocytopenia associated with Grade\>=2(clinically significant)bleeding and Grade4 neutropenia/thrombocytopenia lasting \<7 days. Non-hematological: Grade\>=3 toxicities clinically significant,except those that were not been maximally treated;Grade 2 aspartate aminotransferase(AST), alanine aminotransferase(ALT)/alkaline phosphatase(ALP) levels at baseline as result of liver/bone metastasis,AST,ALT and ALP level\>8\*baseline/AST/ALT \>5\*baseline for\>=14 days; Hy's Law(concomitant ALT/AST elevation of \>=3\*upper limit of normal \[ULN\], total bilirubin elevation\>=2\*ULN without clear alternative etiology); Grade≥3 electrolyte abnormality with clinical sequelae; QTcF prolongation:any Grade\>=3 QT prolongation without clear alternative etiology;any adverse event (AE) attributed to Vepdegestrant and/or PF-07220060 resulting in failure to deliver 75% of doses for either/both agents and any death not clearly due to underlying disease/extraneous causes.
Time frame: Cycle 1 (28 days)
Percentage of Participants With Confirmed Objective Response (OR) by Derived Investigator Assessment: Phase 2
OR was defined as best overall response (BOR) of confirmed complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors (RECIST) version (v) 1.1. CR was defined as complete disappearance of all target lesions, except for nodal disease, complete disappearance of all non-target lesions and no new lesions. All nodes, both target and non-target, must decrease to normal (short axis \<10 millimeter \[mm\]). PR was defined as at least a \>=30% decrease from baseline in the sum of diameters of all target lesions. The short diameter was used in the sum for nodal target lesions, while the longest diameter was used in the sum for non-nodal target lesions, all target lesions were assessed.
Time frame: From the date of first dose of study treatment combination until the first documentation of disease progression (PD), death or start of new anticancer therapy, whichever occurred first (maximum treatment exposure of 9.5 months for Phase 2)
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Treatment Related TEAEs: Phase 1b
AE: any untoward medical occurrence in clinical study participant, temporally associated with use of study treatment, whether or not considered related to study treatment. Serious adverse event (SAE): any untoward medical occurrence, at any dose met one or more of following criteria: death, life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect or other important medical events. AEs includes both SAEs and all other AEs (non-SAEs). TEAEs will be those events with onset dates occurring during the on-treatment period. Relatedness to study drug judged by investigator.
Time frame: From the date of first dose of study treatment combination through study completion
Number of Participants With Laboratory Abnormalities: Phase 1b
Laboratory parameters assessed: hemoglobin, platelets, white blood cells (WBC), absolute neutrophils, absolute lymphocytes, absolute monocytes, absolute eosinophils, absolute basophils, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), sodium, potassium, magnesium, chloride, total calcium, total bilirubin, urea or blood urea nitrogen (BUN), creatinine, estimated glomerular filtration rate (eGFR), uric acid, glucose (fasted), albumin, phosphorus, lipase and amylase.
Time frame: From the date of first dose of study treatment combination through study completion
Number of Participants With Electrocardiogram (ECG) Abnormalities: Phase 1b
Twelve lead ECGs were measured with the participant in a supine position after at least 5 minutes.
Time frame: From the date of first dose of study treatment combination through study completion
Percentage of Participants With Confirmed OR by Derived Investigator Assessment: Phase 1b
OR was defined as BOR of confirmed CR or PR according to RECIST v 1.1. CR was defined as complete disappearance of all target lesions, except for nodal disease, complete disappearance of all non-target lesions and no new lesions. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). PR was defined as at least a \>=30% decrease from baseline in the sum of diameters of all target lesions. The short diameter was used in the sum for nodal target lesions, while the longest diameter was used in the sum for non-nodal target lesions, all target lesions were assessed.
Time frame: From the date of first dose of study treatment combination through study completion
Duration of Response (DOR) by Derived Investigator Assessment: Phase 1b
DoR: for participants with OR: time from first documentation of CR/PR to first documentation of PD/death. CR: complete disappearance of all target lesions (L), except nodal disease, complete disappearance of all non-target L and no new L. Both target and non-target nodes, must decrease to normal. PR: \>=30% decrease from baseline in sum of diameters of target L. Short diameter used in sum for nodal target L, longest diameter used in sum for non-nodal target L. PD: 20% increase in sum of diameter of target measurable L above smallest sum observed, minimum absolute increase of 5 mm for target L/unequivocal progression of pre-existing L for non-target L. DOR censored on date of last adequate disease assessment for participants who did not have DOR event, discontinued study treatment due to withdrawal of consent prior to event, started new anticancer therapy prior to event, had event after gap of \>2 missing disease assessments, or lost to follow-up. Kaplan-Meier method will be used.
Time frame: From the date of first dose of study treatment combination through study completion
Clinical Benefit Response (CBR) by Derived Investigator Assessment: Phase 1b
CBR was defined as percentage of participants with BOR of confirmed CR or PR at any time, or stable disease (SD) \>=24 weeks as per RECIST v1.1. CR: complete disappearance of all target lesions, except for nodal disease, complete disappearance of all non-target lesions and no new lesions. All nodes, both target and non-target, must decrease to normal (short axis\<10 mm). PR: at least \>=30% decrease from baseline in sum of diameters of all target lesions. Short diameter was used in sum for nodal target lesions, while longest diameter was used in sum for non-nodal target lesions, all target lesions were assessed. SD: did not qualify for CR, PR, PD. All target lesions were assessed. PD: 20% increase in sum of diameters of target measurable lesions above smallest sum observed, minimum absolute increase of 5mm for target lesions/unequivocal progression of pre-existing lesions for non-target lesion.
Time frame: From the date of first dose of study treatment combination through study completion
Progression Free Survival (PFS) by Derived Investigator Assessment: Phase 1b
PFS was defined as the time from the date of first dose of study interventions to the date of first documentation of PD or death due to any cause, whichever occurred first as per RECIST v1.1. PD: 20% increase in sum of diameters of target measurable lesions above smallest sum observed, minimum absolute increase of 5mm for target lesions/unequivocal progression of pre-existing lesions for non-target lesion. PFS was censored on the date of last adequate disease assessment for those who did not have a PFS event, discontinued the study treatment due to withdrawal of consent prior to an event, started a new anticancer therapy prior to an event, had an event after a gap of 2 or more missing disease assessments, or lost to follow-up. Kaplan-Meier method will be used.
Time frame: From the date of first dose of study treatment combination through study completion
Plasma Concentration of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 1b
Plasma concentrations of ARV-471 and its epimer ARV-473 were reported in this outcome measure.
Time frame: Cycle 1, Day 8: Pre-dose; Cycle 1 Day 15: Pre-dose, 30 minutes, 1, 2, 4 ,6, 8 and 12 hours post-dose; Cycle 2 Days 1 and 15: Pre-dose, anytime between 4 to 8 hour post-dose; Cycles 3, 5, and 7, Day 1: Pre-dose
Plasma Concentration of PF-07220060: Phase 1b
Time frame: Pre-dose (0 hour) of Day 8 of Cycle 1; pre-dose (0 hour), 0.5,1,2,4,6,8 and 12 hours post-dose of Day 15 of Cycle 1; Pre-dose (0 hour) and anytime between 4 to 8 hour post-dose of Day 1 and 15 of Cycle 2; Pre-dose (0 hour) of Day 1 of Cycle 3, 5 and 7
Steady State Maximum Observed Plasma Concentration (Cmax,ss) of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 1b
Cmax,ss was the steady-state maximum concentration of ARV-471 after multiple doses and was directly observed from data. ARV-473 is an epimer of ARV-471.
Time frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
Cmax,ss of PF-07220060: Phase 1b
Time frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
Steady State Time to Maximum Plasma Concentration (Tmax,ss) of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 1b
Tmax,ss was the steady-state time to maximum plasma concentration after multiple doses and was directly observed from data. ARV-473 is an epimer of ARV-471. ARV-473 is an epimer of ARV-471.
Time frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
Tmax,ss of PF-07220060: Phase 1b
Tmax,ss was the steady-state time to maximum plasma concentration after multiple doses and was directly observed from data.
Time frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
Steady State Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast,ss) of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 1b
AUClast,ss was defined as area under the plasma concentration time curve from time zero to the last measurable concentration as steady state. AUClast,ss was calculated using linear/log trapezoidal method.
Time frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
AUClast,ss of PF-07220060: Phase 1b
AUClast,ss was defined as area under the plasma concentration time curve from time zero to the last measurable concentration as steady state. AUClast,ss was calculated using linear/log trapezoidal method.
Time frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
Apparent Total Clearance (CL/F) of Vepdegestrant (ARV-471): Phase 1b
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose administered divided by AUCinf. AUCinf was calculated as AUClast + (Clast/kel), where, AUClast= area under the concentration-time curve from time 0 to time of last measurable concentration, Clast was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Time frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
CL/F of PF-07220060: Phase 1b
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose administered divided by AUCinf. AUCinf was calculated as AUClast + (Clast/kel), where, AUClast= area under the concentration-time curve from time 0 to time of last measurable concentration, Clast was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Time frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
Apparent Volume of Distribution (Vz/F) of PF-07220060: Phase 1b
Vz/F was calculated as Dose/(AUCinf \* kel). AUCinf was calculated as AUClast + (Clast/kel), where, AUClast= area under the concentration-time curve from time 0 to time of last measurable concentration, Clast was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Time frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
Terminal Half-Life (t1/2) of PF-07220060: Phase 1b
T1/2 was calculated as loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Time frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
DOR by Derived Investigator Assessment: Phase 2
DOR: for participants with OR: time from first documentation of CR/PR to first documentation of PD/death. CR: complete disappearance of all target lesions (L), except nodal disease, complete disappearance of all non-target L and no new L. Both target and non-target nodes, must decrease to normal. PR: \>=30% decrease from baseline in sum of diameters of target L. Short diameter used in sum for nodal target L, longest diameter used in sum for non-nodal target L. PD: 20% increase in sum of diameter of target measurable L above smallest sum observed, minimum absolute increase of 5 mm for target L/unequivocal progression of pre-existing L for non-target L. DOR censored on date of last adequate disease assessment for participants who did not have DOR event, discontinued study treatment due to withdrawal of consent prior to event, started new anticancer therapy prior to event, had event after gap of \>2 missing disease assessments, or lost to follow-up. Kaplan-Meier method will be used.
Time frame: From the date of first dose of study treatment combination through study completion
Percentage of Participants With CBR by Derived Investigator Assessment: Phase 2
CBR was defined as percentage of participants with BOR of confirmed CR or PR at any time, or stable disease (SD) \>=24 weeks as per RECIST v1.1. CR: complete disappearance of all target lesions, except for nodal disease, complete disappearance of all non-target lesions and no new lesions. All nodes, both target and non-target, must decrease to normal (short axis\<10 mm). PR: at least \>=30% decrease from baseline in sum of diameters of all target lesions. Short diameter was used in sum for nodal target lesions, while longest diameter was used in sum for non-nodal target lesions, all target lesions were assessed. SD: did not qualify for CR, PR, PD. All target lesions were assessed. PD: 20% increase in sum of diameters of target measurable lesions above smallest sum observed, minimum absolute increase of 5mm for target lesions/unequivocal progression of pre-existing lesions for non-target lesion.
Time frame: From the date of first dose of study treatment combination through study completion
PFS by Derived Investigator Assessment: Phase 2
PFS was defined as the time from the date of first dose of study interventions to the date of first documentation of PD or death due to any cause, whichever occurred first as per RECIST v1.1. PD: 20% increase in sum of diameters of target measurable lesions above smallest sum observed, minimum absolute increase of 5mm for target lesions/unequivocal progression of pre-existing lesions for non-target lesion. PFS was censored on the date of last adequate disease assessment for those who did not have a PFS event, discontinued the study treatment due to withdrawal of consent prior to an event, started a new anticancer therapy prior to an event, had an event after a gap of 2 or more missing disease assessments, or lost to follow-up. Kaplan-Meier method will be used.
Time frame: From the date of first dose of study treatment combination through study completion
Overall Survival (OS): Phase 2
OS was defined as the time from the date of first dose of study treatment combination to the date of death due to any cause. Participants last known to be alive were censored at the date of last contact. Kaplan-Meier method will be used.
Time frame: From the date of first dose of study treatment combination through study completion
Number of Participants With TEAEs, TESAEs and Treatment Related TEAEs: Phase 2
AE: any untoward medical occurrence in clinical study participant, temporally associated with use of study treatment, whether or not considered related to study treatment. SAE: any untoward medical occurrence, at any dose met one or more of following criteria: death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect or other important medical events. AEs includes both SAEs and all other AEs (non-SAEs). TEAEs will be those events with onset dates occurring during the on-treatment period. Relatedness to study drug judged by investigator.
Time frame: From the date of first dose of study treatment combination through study completion
Number of Participants With ECG Abnormalities: Phase 2
Twelve lead ECGs were measured with the participant in a supine position after at least 5 minutes.
Time frame: From the date of first dose of study treatment combination through study completion
Number of Participants With Laboratory Abnormalities: Phase 2
Laboratory parameters assessed included hemoglobin, platelets, WBC, absolute neutrophils, absolute lymphocytes, absolute monocytes, absolute eosinophils, absolute basophils, ALT, AST, ALP, sodium, potassium, magnesium, chloride, total calcium, total bilirubin, urea or BUN, creatinine, eGFR, uric acid, glucose (fasted), albumin, phosphorus, lipase and amylase.
Time frame: From the date of first dose of study treatment combination through study completion
Plasma Concentration of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 2
Plasma concentrations of ARV-471 and its epimer ARV-473 were reported in this outcome measure.
Time frame: Cycle 1, Day 15 and Cycle 2 Days 1 and 15: Pre-dose, anytime between 4 to 8 hour post-dose; Cycles 3, 5, and 7, Day 1: Pre-dose
Plasma Concentration of PF-07220060: Phase 2
Plasma concentrations of ARV-471 and its epimer ARV-473 were reported in this outcome measure.
Time frame: Cycle 1, Day 15 and Cycle 2 Days 1 and 15: Pre-dose, anytime between 4 to 8 hours post-dose; Cycles 3, 5, and 7, Day 1: Pre-dose
Change From Baseline in Circulating Tumor Deoxyribonucleic Acid (ctDNA) Plasma Level: Phase 2
Time frame: Baseline and up to End of Treatment
| Milestone | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID | Phase 2: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 2: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID |
|---|---|---|---|---|
| Started | 9 | 7 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 9 | 7 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 5 | 3 | 0 | 0 |
| Withdrew: Other | 1 | 0 | 0 | 0 |
| Withdrew: Ongoing | 2 | 3 | 0 | 0 |
| Milestone | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID | Phase 2: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 2: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID |
|---|---|---|---|---|
| Started | 9 | 7 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 9 | 7 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 5 | 3 | 0 | 0 |
| Withdrew: Other | 1 | 0 | 0 | 0 |
| Withdrew: Ongoing | 2 | 3 | 0 | 0 |
| Milestone | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID | Phase 2: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 2: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID |
|---|---|---|---|---|
| Started | 0 | 0 | 27 | 28 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 27 | 28 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
| Withdrew: Progressive disease | 0 | 0 | 9 | 12 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 |
| Withdrew: Global deterioration of health status | 0 | 0 | 1 | 0 |
| Withdrew: Other | 0 | 0 | 2 | 0 |
| Withdrew: Ongoing | 0 | 0 | 14 | 14 |
| Withdrew: Randomized but not treated | 0 | 0 | 0 | 1 |
| Milestone | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID | Phase 2: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 2: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID |
|---|---|---|---|---|
| Started | 0 | 0 | 27 | 28 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 27 | 28 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
| Withdrew: Progressive disease | 0 | 0 | 10 | 12 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 |
| Withdrew: Global deterioration of health status | 0 | 0 | 1 | 0 |
| Withdrew: Other | 0 | 0 | 2 | 0 |
| Withdrew: Ongoing | 0 | 0 | 13 | 14 |
| Withdrew: Randomized but not treated | 0 | 0 | 0 | 1 |
Hematological DLT: neutropenic fever; Grade\>=3 thrombocytopenia associated with Grade\>=2(clinically significant)bleeding and Grade4 neutropenia/thrombocytopenia lasting \<7 days. Non-hematological: Grade\>=3 toxicities clinically significant,except those that were not been maximally treated;Grade 2 aspartate aminotransferase(AST), alanine aminotransferase(ALT)/alkaline phosphatase(ALP) levels at baseline as result of liver/bone metastasis,AST,ALT and ALP level\>8\*baseline/AST/ALT \>5\*baseline for\>=14 days; Hy's Law(concomitant ALT/AST elevation of \>=3\*upper limit of normal \[ULN\], total bilirubin elevation\>=2\*ULN without clear alternative etiology); Grade≥3 electrolyte abnormality with clinical sequelae; QTcF prolongation:any Grade\>=3 QT prolongation without clear alternative etiology;any adverse event (AE) attributed to Vepdegestrant and/or PF-07220060 resulting in failure to deliver 75% of doses for either/both agents and any death not clearly due to underlying disease/extraneous causes.
| Participants | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID |
|---|---|---|
| Number of Participants With Dose-Limiting Toxicities (DLTs): Phase 1b | 1 | 1 |
OR was defined as best overall response (BOR) of confirmed complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors (RECIST) version (v) 1.1. CR was defined as complete disappearance of all target lesions, except for nodal disease, complete disappearance of all non-target lesions and no new lesions. All nodes, both target and non-target, must decrease to normal (short axis \<10 millimeter \[mm\]). PR was defined as at least a \>=30% decrease from baseline in the sum of diameters of all target lesions. The short diameter was used in the sum for nodal target lesions, while the longest diameter was used in the sum for non-nodal target lesions, all target lesions were assessed.
| Percentage of participants | Phase 2: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 2: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID |
|---|---|---|
| Percentage of Participants With Confirmed Objective Response (OR) by Derived Investigator Assessment: Phase 2 | 18.5 (8.2 to 36.7) | 22.2 (10.6 to 40.8) |
AE: any untoward medical occurrence in clinical study participant, temporally associated with use of study treatment, whether or not considered related to study treatment. Serious adverse event (SAE): any untoward medical occurrence, at any dose met one or more of following criteria: death, life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect or other important medical events. AEs includes both SAEs and all other AEs (non-SAEs). TEAEs will be those events with onset dates occurring during the on-treatment period. Relatedness to study drug judged by investigator.
Results for this outcome have not been posted.
Laboratory parameters assessed: hemoglobin, platelets, white blood cells (WBC), absolute neutrophils, absolute lymphocytes, absolute monocytes, absolute eosinophils, absolute basophils, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), sodium, potassium, magnesium, chloride, total calcium, total bilirubin, urea or blood urea nitrogen (BUN), creatinine, estimated glomerular filtration rate (eGFR), uric acid, glucose (fasted), albumin, phosphorus, lipase and amylase.
Results for this outcome have not been posted.
Twelve lead ECGs were measured with the participant in a supine position after at least 5 minutes.
Results for this outcome have not been posted.
OR was defined as BOR of confirmed CR or PR according to RECIST v 1.1. CR was defined as complete disappearance of all target lesions, except for nodal disease, complete disappearance of all non-target lesions and no new lesions. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). PR was defined as at least a \>=30% decrease from baseline in the sum of diameters of all target lesions. The short diameter was used in the sum for nodal target lesions, while the longest diameter was used in the sum for non-nodal target lesions, all target lesions were assessed.
Results for this outcome have not been posted.
DoR: for participants with OR: time from first documentation of CR/PR to first documentation of PD/death. CR: complete disappearance of all target lesions (L), except nodal disease, complete disappearance of all non-target L and no new L. Both target and non-target nodes, must decrease to normal. PR: \>=30% decrease from baseline in sum of diameters of target L. Short diameter used in sum for nodal target L, longest diameter used in sum for non-nodal target L. PD: 20% increase in sum of diameter of target measurable L above smallest sum observed, minimum absolute increase of 5 mm for target L/unequivocal progression of pre-existing L for non-target L. DOR censored on date of last adequate disease assessment for participants who did not have DOR event, discontinued study treatment due to withdrawal of consent prior to event, started new anticancer therapy prior to event, had event after gap of \>2 missing disease assessments, or lost to follow-up. Kaplan-Meier method will be used.
Results for this outcome have not been posted.
CBR was defined as percentage of participants with BOR of confirmed CR or PR at any time, or stable disease (SD) \>=24 weeks as per RECIST v1.1. CR: complete disappearance of all target lesions, except for nodal disease, complete disappearance of all non-target lesions and no new lesions. All nodes, both target and non-target, must decrease to normal (short axis\<10 mm). PR: at least \>=30% decrease from baseline in sum of diameters of all target lesions. Short diameter was used in sum for nodal target lesions, while longest diameter was used in sum for non-nodal target lesions, all target lesions were assessed. SD: did not qualify for CR, PR, PD. All target lesions were assessed. PD: 20% increase in sum of diameters of target measurable lesions above smallest sum observed, minimum absolute increase of 5mm for target lesions/unequivocal progression of pre-existing lesions for non-target lesion.
Results for this outcome have not been posted.
PFS was defined as the time from the date of first dose of study interventions to the date of first documentation of PD or death due to any cause, whichever occurred first as per RECIST v1.1. PD: 20% increase in sum of diameters of target measurable lesions above smallest sum observed, minimum absolute increase of 5mm for target lesions/unequivocal progression of pre-existing lesions for non-target lesion. PFS was censored on the date of last adequate disease assessment for those who did not have a PFS event, discontinued the study treatment due to withdrawal of consent prior to an event, started a new anticancer therapy prior to an event, had an event after a gap of 2 or more missing disease assessments, or lost to follow-up. Kaplan-Meier method will be used.
Results for this outcome have not been posted.
Plasma concentrations of ARV-471 and its epimer ARV-473 were reported in this outcome measure.
| Nanogram per milliliter (ng/mL) | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID |
|---|---|---|
| ARV-471: Cycle 1 Day 8 (Pre-dose) | 375.0 ± 104.99 | 508.3 ± 235.65 |
| ARV-471: Cycle 1 Day 15 (Pre-dose) | 468.4 ± 164.97 | 567.0 ± 89.601 |
| ARV-471: Cycle 1 Day 15 (0.5-hour Post-dose) | 476.2 ± 149.9 | 571.8 ± 83.548 |
| ARV-471: Cycle 1 Day 15 (1-hour Post-dose) | 557.9 ± 192.94 | 593.6 ± 143.79 |
| ARV-471: Cycle 1 Day 15 (2-hour Post-dose) | 673.4 ± 271.02 | 699.4 ± 153.54 |
| ARV-471: Cycle 1 Day 15 (4-hour Post-dose) | 924.4 ± 385.02 | 754.8 ± 136.3 |
| ARV-471: Cycle 1 Day 15 (6-hour Post-dose) | 864.3 ± 311.86 | 735.8 ± 134.9 |
| ARV-471: Cycle 1 Day 15 (8-hour Post-dose) | 822.1 ± 229.43 | 798.5 ± 307.54 |
| ARV-471: Cycle 1 Day 15 (12-hour Post-dose) | 772.9 ± 197.54 | 650.6 ± 132.92 |
| ARV-471: Cycle 2 Day 1 (Pre-dose) | 418.2 ± 203.74 | 482.0 ± 261.75 |
| ARV-471: Cycle 2 Day 1 (4-8 hour Post-dose) | 875.1 ± 325.67 | 1015 ± 611.37 |
| ARV-471: Cycle 2 Day 15 (Pre-dose) | 376.6 ± 124.07 | 492.0 ± 225.87 |
| ARV-471: Cycle 2 Day 15 (4-8 hour Post-dose) | 727.4 ± 224.68 | 1044 ± 601.31 |
| ARV-471: Cycle 3 Day 1 (Pre-dose) | 280.4 ± 208.3 | 474.3 ± 168.69 |
| ARV-471: Cycle 5 Day 1 (Pre-dose) | 234.6 ± 195.5 | 520.3 ± 109.65 |
| ARV-471: Cycle 7 Day 1 (Pre-dose) | 465.0 ± 348.17 | 562.7 ± 246.13 |
| ARV-473: Cycle 1 Day 8 (Pre-dose) | 162.5 ± 56.484 | 212.3 ± 105.56 |
| ARV-473: Cycle 1 Day 15 (Pre-dose) | 191.9 ± 81.727 | 252.2 ± 73.538 |
| ARV-473: Cycle 1 Day 15 (0.5-hour Post-dose) | 190.8 ± 74.231 | 242.0 ± 54.724 |
| ARV-473: Cycle 1 Day 15 (1-hour Post-dose) | 196.2 ± 81.734 | 228.2 ± 65.194 |
| ARV-473: Cycle 1 Day 15 (2-hour Post-dose) | 198.3 ± 81.097 | 235.4 ± 70.515 |
| ARV-473: Cycle 1 Day 15 (4-hour Post-dose) | 226.8 ± 85.994 | 240.4 ± 67.534 |
| ARV-473: Cycle 1 Day 15 (6-hour Post-dose) | 234.7 ± 97.739 | 252.2 ± 69.309 |
| ARV-473: Cycle 1 Day 15 (8-hour Post-dose) | 231.2 ± 94.873 | 274.0 ± 89.971 |
| ARV-473: Cycle 1 Day 15 (12-hour Post-dose) | 239.8 ± 87.325 | 247.0 ± 75.432 |
| ARV-473: Cycle 2 Day 1 (Pre-dose) | 182.8 ± 95.3 | 219.4 ± 132.45 |
| ARV-473: Cycle 2 Day 1 (4-8 hour Post-dose) | 215.3 ± 88.692 | 289.2 ± 173.68 |
| ARV-473: Cycle 2 Day 15 (Pre-dose) | 161.1 ± 57.394 | 210.8 ± 94.977 |
| ARV-473: Cycle 2 Day 15 (4-8 hour Post-dose) | 193.7 ± 64.42 | 281.3 ± 136.33 |
| ARV-473: Cycle 3 Day 1 (Pre-dose) | 124.4 ± 84.322 | 217.4 ± 95.033 |
| ARV-473: Cycle 5 Day 1 (Pre-dose) | 124.4 ± 89.004 | 242.5 ± 69.869 |
| ARV-473: Cycle 7 Day 1 (Pre-dose) | 186.4 ± 113.54 | 225.3 ± 95.824 |
| ng/mL | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID |
|---|---|---|
| Day 8 Cycle 1 (Pre-dose) | 460.7 ± 232.49 | 931.3 ± 390.16 |
| Day 15 Cycle 1 (Pre-dose) | 439.7 ± 203.91 | 742.8 ± 206.47 |
| Day 15 Cycle 1 (0.5 hour Post- dose) | 510.4 ± 199.78 | 824.5 ± 268.93 |
| Day 15 Cycle 1 (1 hour Post- dose) | 588.9 ± 249.77 | 915.8 ± 244.79 |
| Day 15 Cycle 1 (2 hour Post- dose) | 739.6 ± 450.37 | 941.6 ± 196.25 |
| Day 15 Cycle 1 (4 hour Post- dose) | 698.0 ± 397.07 | 818.2 ± 207.73 |
| Day 15 Cycle 1 (6 hour Post- dose) | 571.0 ± 290.69 | 641.6 ± 207.47 |
| Day 15 Cycle 1 (8 hour Post- dose) | 472.9 ± 190.36 | 616.0 ± 285.36 |
| Day 15 Cycle 1 (12 hour Post- dose) | 412.1 ± 162.65 | 515.3 ± 335.06 |
| Day 1 Cycle 2 (Pre-dose) | 426.7 ± 216.56 | 697.5 ± 363.98 |
| Day 1 Cycle 2 (4-8 hour Post- dose) | 744.9 ± 770.09 | 1117 ± 656.23 |
| Day 15 Cycle 2 (Pre-dose) | 330.0 ± 119.7 | 794.6 ± 408.27 |
| Day 15 Cycle 2 (4-8 hour Post- dose) | 472.3 ± 106.81 | 968.2 ± 518.43 |
| Day 1 Cycle 3 (Pre-dose) | 276.4 ± 264.85 | 911.5 ± 411.37 |
| Day 1 Cycle 5 (Pre-dose) | 161.8 ± 156.45 | 926.8 ± 431.03 |
| Day 1 Cycle 7 (Pre-dose) | 158.1 ± 130.06 | 798.0 ± 537.58 |
Cmax,ss was the steady-state maximum concentration of ARV-471 after multiple doses and was directly observed from data. ARV-473 is an epimer of ARV-471.
| ng/mL | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID |
|---|---|---|
| ARV-471 | 938.6 ± 33 | 876.6 ± 43 |
| ARV-473 | 234.6 ± 38 | 278.5 ± 35 |
| ng/mL | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID |
|---|---|---|
| Cmax,ss of PF-07220060: Phase 1b | 699.8 ± 53 | 1028 ± 29 |
Tmax,ss was the steady-state time to maximum plasma concentration after multiple doses and was directly observed from data. ARV-473 is an epimer of ARV-471. ARV-473 is an epimer of ARV-471.
| Hours | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID |
|---|---|---|
| ARV-471 | 4.08 (3.8 to 10.0) | 3.98 (1.97 to 7.63) |
| ARV-473 | 7.97 (3.87 to 10.2) | 6.02 (2.77 to 10.0) |
Tmax,ss was the steady-state time to maximum plasma concentration after multiple doses and was directly observed from data.
| Hours | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID |
|---|---|---|
| Tmax,ss of PF-07220060: Phase 1b | 2.05 (1.05 to 5.97) | 1.42 (0.683 to 2.1) |
AUClast,ss was defined as area under the plasma concentration time curve from time zero to the last measurable concentration as steady state. AUClast,ss was calculated using linear/log trapezoidal method.
| Nanogram*hour per milliliter (ng*hr/mL) | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID |
|---|---|---|
| ARV-471 | 7505 ± 33 | 7580 ± 31 |
| ARV-473 | 2100 ± 38 | 2544 ± 33 |
AUClast,ss was defined as area under the plasma concentration time curve from time zero to the last measurable concentration as steady state. AUClast,ss was calculated using linear/log trapezoidal method.
| ng*hr/mL | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID |
|---|---|---|
| AUClast,ss of PF-07220060: Phase 1b | 5269 ± 48 | 7028 ± 34 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose administered divided by AUCinf. AUCinf was calculated as AUClast + (Clast/kel), where, AUClast= area under the concentration-time curve from time 0 to time of last measurable concentration, Clast was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
| Liters per hour (L/hr) | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID |
|---|---|---|
| Apparent Total Clearance (CL/F) of Vepdegestrant (ARV-471): Phase 1b | 12.75 ± 29 | 12.02 ± 30 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose administered divided by AUCinf. AUCinf was calculated as AUClast + (Clast/kel), where, AUClast= area under the concentration-time curve from time 0 to time of last measurable concentration, Clast was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
| L/hr | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID |
|---|---|---|
| CL/F of PF-07220060: Phase 1b | — | 51.7 |
Vz/F was calculated as Dose/(AUCinf \* kel). AUCinf was calculated as AUClast + (Clast/kel), where, AUClast= area under the concentration-time curve from time 0 to time of last measurable concentration, Clast was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
| Liters | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID |
|---|---|---|
| Apparent Volume of Distribution (Vz/F) of PF-07220060: Phase 1b | — | 295 |
T1/2 was calculated as loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
| Hours | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID |
|---|---|---|
| Terminal Half-Life (t1/2) of PF-07220060: Phase 1b | — | 3.96 |
DOR: for participants with OR: time from first documentation of CR/PR to first documentation of PD/death. CR: complete disappearance of all target lesions (L), except nodal disease, complete disappearance of all non-target L and no new L. Both target and non-target nodes, must decrease to normal. PR: \>=30% decrease from baseline in sum of diameters of target L. Short diameter used in sum for nodal target L, longest diameter used in sum for non-nodal target L. PD: 20% increase in sum of diameter of target measurable L above smallest sum observed, minimum absolute increase of 5 mm for target L/unequivocal progression of pre-existing L for non-target L. DOR censored on date of last adequate disease assessment for participants who did not have DOR event, discontinued study treatment due to withdrawal of consent prior to event, started new anticancer therapy prior to event, had event after gap of \>2 missing disease assessments, or lost to follow-up. Kaplan-Meier method will be used.
Results for this outcome have not been posted.
CBR was defined as percentage of participants with BOR of confirmed CR or PR at any time, or stable disease (SD) \>=24 weeks as per RECIST v1.1. CR: complete disappearance of all target lesions, except for nodal disease, complete disappearance of all non-target lesions and no new lesions. All nodes, both target and non-target, must decrease to normal (short axis\<10 mm). PR: at least \>=30% decrease from baseline in sum of diameters of all target lesions. Short diameter was used in sum for nodal target lesions, while longest diameter was used in sum for non-nodal target lesions, all target lesions were assessed. SD: did not qualify for CR, PR, PD. All target lesions were assessed. PD: 20% increase in sum of diameters of target measurable lesions above smallest sum observed, minimum absolute increase of 5mm for target lesions/unequivocal progression of pre-existing lesions for non-target lesion.
Results for this outcome have not been posted.
PFS was defined as the time from the date of first dose of study interventions to the date of first documentation of PD or death due to any cause, whichever occurred first as per RECIST v1.1. PD: 20% increase in sum of diameters of target measurable lesions above smallest sum observed, minimum absolute increase of 5mm for target lesions/unequivocal progression of pre-existing lesions for non-target lesion. PFS was censored on the date of last adequate disease assessment for those who did not have a PFS event, discontinued the study treatment due to withdrawal of consent prior to an event, started a new anticancer therapy prior to an event, had an event after a gap of 2 or more missing disease assessments, or lost to follow-up. Kaplan-Meier method will be used.
Results for this outcome have not been posted.
OS was defined as the time from the date of first dose of study treatment combination to the date of death due to any cause. Participants last known to be alive were censored at the date of last contact. Kaplan-Meier method will be used.
Results for this outcome have not been posted.
AE: any untoward medical occurrence in clinical study participant, temporally associated with use of study treatment, whether or not considered related to study treatment. SAE: any untoward medical occurrence, at any dose met one or more of following criteria: death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect or other important medical events. AEs includes both SAEs and all other AEs (non-SAEs). TEAEs will be those events with onset dates occurring during the on-treatment period. Relatedness to study drug judged by investigator.
Results for this outcome have not been posted.
Twelve lead ECGs were measured with the participant in a supine position after at least 5 minutes.
Results for this outcome have not been posted.
Laboratory parameters assessed included hemoglobin, platelets, WBC, absolute neutrophils, absolute lymphocytes, absolute monocytes, absolute eosinophils, absolute basophils, ALT, AST, ALP, sodium, potassium, magnesium, chloride, total calcium, total bilirubin, urea or BUN, creatinine, eGFR, uric acid, glucose (fasted), albumin, phosphorus, lipase and amylase.
Results for this outcome have not been posted.
Plasma concentrations of ARV-471 and its epimer ARV-473 were reported in this outcome measure.
| ng/mL | Phase 2: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 2: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID |
|---|---|---|
| ARV-471: Cycle 1 Day 15 (Pre-dose) | 449.4 ± 178.42 | 478.4 ± 191.59 |
| ARV-471: Cycle 1 Day 15 (4-8 hour Post-dose) | 886.8 ± 321.78 | 895.8 ± 339.54 |
| ARV-471: Cycle 2 Day 1 (Pre-dose) | 433.3 ± 164.75 | 403.3 ± 184.21 |
| ARV-471: Cycle 2 Day 1 (4-8 hour Post-dose) | 795.6 ± 322.46 | 793.1 ± 303.95 |
| ARV-471: Cycle 2 Day 15 (Pre-dose) | 433.6 ± 185.66 | 477.8 ± 232.24 |
| ARV-471: Cycle 2 Day 15 (4-8 hour Post-dose) | 848.2 ± 280.9 | 904.2 ± 419.08 |
| ARV-471: Cycle 3 Day 1 (Pre-dose) | 414.9 ± 180.37 | 435.9 ± 194.19 |
| ARV-471: Cycle 5 Day 1 (Pre-dose) | 373.1 ± 233.75 | 465.8 ± 138.87 |
| ARV-471: Cycle 7 Day 1 (Pre-dose) | 427.6 ± 195.86 | 487.4 ± 122.95 |
| ARV-473: Cycle 1 Day 15 (Pre-dose) | 186.6 ± 75.807 | 202.3 ± 84.462 |
| ARV-473: Cycle 1 Day 15 (4-8 hour Post-dose) | 222.9 ± 91.726 | 230.4 ± 93.664 |
| ARV-473: Cycle 2 Day 1 (Pre-dose) | 184.0 ± 74.338 | 176.4 ± 88.319 |
| ARV-473: Cycle 2 Day 1 (4-8 hour Post-dose) | 208.0 ± 88.597 | 200.1 ± 87.735 |
| ARV-473: Cycle 2 Day 15 (Pre-dose) | 180.3 ± 83.956 | 195.3 ± 82.348 |
| ARV-473: Cycle 2 Day 15 (4-8 hour Post-dose) | 223.8 ± 81.906 | 217.3 ± 101.9 |
| ARV-473: Cycle 3 Day 1 (Pre-dose) | 176.9 ± 77.298 | 192.9 ± 91.457 |
| ARV-473: Cycle 5 Day 1 (Pre-dose) | 155.9 ± 87.197 | 192.5 ± 52.849 |
| ARV-473: Cycle 7 Day 1 (Pre-dose) | 185.6 ± 80.085 | 207.2 ± 46.089 |
Plasma concentrations of ARV-471 and its epimer ARV-473 were reported in this outcome measure.
| ng/mL | Phase 2: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 2: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID |
|---|---|---|
| Cycle 1 Day 15 (Pre-dose) | 485.2 ± 292.69 | 939.5 ± 583.9 |
| Cycle 1 Day 15 (4-8 hour Post-dose) | 481.5 ± 163.82 | 1194 ± 506.16 |
| Cycle 2 Day 1 (Pre-dose) | 415.1 ± 227.66 | 768.3 ± 491.03 |
| Cycle 2 Day 1 (4-8 hour Post-dose) | 491.2 ± 160.38 | 828.4 ± 426.88 |
| Cycle 2 Day 15 (Pre-dose) | 395.3 ± 165.3 | 833.7 ± 517.24 |
| Cycle 2 Day 15 (4-8 hour Post-dose) | 467.2 ± 205.24 | 921.0 ± 362.77 |
| Cycle 3 Day 1 (Pre-dose) | 421.0 ± 216.97 | 724.7 ± 444.27 |
| Cycle 5 Day 1 (Pre-dose) | 379.2 ± 235.37 | 908.7 ± 606.3 |
| Cycle 7 Day 1 (Pre-dose) | 414.6 ± 294.59 | 664.6 ± 212.21 |
Results for this outcome have not been posted.
Collected over From Day 1 of dosing up to 28 days after last dose "maximum up to 16.5 months for Phase 1b and 10.5 months for Phase 2 as maximum treatment exposure was 15.5 months and 9.5 months for Phase 1b and 2 respectively". Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | 1/9 (11.1%) | 4/9 (44.4%) | 9/9 (100%) |
| Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID | 0/7 (0%) | 1/7 (14.3%) | 7/7 (100%) |
| Phase 2: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | 2/27 (7.4%) | 3/27 (11.1%) | 27/27 (100%) |
| Phase 2: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID | 2/27 (7.4%) | 5/27 (18.5%) | 27/27 (100%) |
| Event | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID | Phase 2: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 2: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID |
|---|---|---|---|---|
| Cardiac failureCardiac disorders | 0/9 | 1/7 | 0/27 | 0/27 |
| CellulitisInfections and infestations | 1/9 | 0/7 | 0/27 | 0/27 |
| PneumoniaInfections and infestations | 1/9 | 0/7 | 0/27 | 0/27 |
| Urinary tract infectionInfections and infestations | 1/9 | 0/7 | 0/27 | 0/27 |
| FallInjury, poisoning and procedural complications | 1/9 | 0/7 | 0/27 | 0/27 |
| HypophagiaMetabolism and nutrition disorders | 1/9 | 0/7 | 0/27 | 0/27 |
| NephrolithiasisRenal and urinary disorders | 1/9 | 0/7 | 0/27 | 0/27 |
| DiarrhoeaGastrointestinal disorders | 0/9 | 0/7 | 0/27 | 1/27 |
| Small intestinal obstructionGastrointestinal disorders | 0/9 | 0/7 | 1/27 | 0/27 |
| StomatitisGastrointestinal disorders | 0/9 | 0/7 | 0/27 | 1/27 |
| Event | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID | Phase 2: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 2: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/9 | 4/7 | 6/27 | 14/27 |
| Neutrophil count decreasedInvestigations | 3/9 | 4/7 | 9/27 | 15/27 |
| NauseaGastrointestinal disorders | 2/9 | 1/7 | 8/27 | 12/27 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/9 | 0/7 | 6/27 | 4/27 |
| FatigueGeneral disorders | 3/9 | 3/7 | 9/27 | 7/27 |
| PruritusSkin and subcutaneous tissue disorders | 2/9 | 3/7 | 3/27 | 1/27 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/9 | 1/7 | 10/27 | 2/27 |
| VomitingGastrointestinal disorders | 3/9 | 1/7 | 3/27 | 5/27 |
| White blood cell count decreasedInvestigations | 3/9 | 2/7 | 6/27 | 9/27 |
| Electrocardiogram QT prolongedInvestigations | 2/9 | 1/7 | 8/27 | 1/27 |
Safety analysis set included all enrolled participants assigned to study intervention and who took at least 1 dose of either vepdegestrant or PF-07220060 study intervention.
| Age, Continuous(Years) | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID | Phase 2: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 2: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID | Total |
|---|---|---|---|---|---|
| Mean | 60.1 ± 8.62 | 71.7 ± 10.64 | 58.8 ± 12.28 | 57.4 ± 11.26 | 59.7 ± 11.84 |
| Sex: Female, Male(Participants) | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID | Phase 2: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 2: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID | Total |
|---|---|---|---|---|---|
| Female | 9 | 7 | 26 | 27 | 69 |
| Male | 0 | 0 | 1 | 0 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID | Phase 2: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 2: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 5 | 2 | 10 |
| Not Hispanic or Latino | 6 | 6 | 20 | 23 | 55 |
| Unknown or Not Reported | 1 | 0 | 2 | 2 | 5 |
| Race (NIH/OMB)(Participants) | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID | Phase 2: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID | Phase 2: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 3 | 3 | 9 | 7 | 22 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 0 | 1 |
| White | 6 | 4 | 15 | 18 | 43 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 2 | 2 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Feb 2024 to primary completion in Sep 2025, 18 months.
Results were first posted in Sep 2026, 1 year after primary completion.
Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's 18 months is below that.
Counting every sponsor, half of 328 studies reached it within 61 months; a quarter within 45 and three quarters within 88.
Completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → May 2027, on Sep 30, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Vepdegestrant · Atirmociclib